| Publications | PubMed=954005
Zielske J.V., Golub S.H.
Fetal calf serum-induced blastogenic and cytotoxic responses of human lymphocytes.
Cancer Res. 36:3842-3846(1976) PubMed=945229; DOI=10.1002/ijc.2910170408
Sulit H.L., Golub S.H., Irie R.F., Gupta R.K., Grooms G.A., Morton D.L.
Human tumor cells grown in fetal calf serum and human serum: influences on the tests for lymphocyte cytotoxicity, serum blocking and serum arming effects.
Int. J. Cancer 17:461-468(1976) PubMed=1260767
Chee D.O., Boddie A.W., Roth J.A., Holmes E.C., Morton D.L.
Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.
Cancer Res. 36:1503-1509(1976) PubMed=204583; DOI=10.1002/ijc.2910210308
Saxton R.E., Irie R.F., Ferrone S., Pellegrino M.A., Morton D.L.
Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients.
Int. J. Cancer 21:299-306(1978) PubMed=6876798; DOI=10.1002/jso.2930230404
Chee D.O., Gupta R.K., Morton D.L.
Humoral response of melanoma patients to two different tumor-associated antigens.
J. Surg. Oncol. 23:228-235(1983) PubMed=6470027; DOI=10.1007/BF00402467
Katano M., Saxton R.E., Cochran A.J., Irie R.F.
Establishment of an ascitic human melanoma cell line that metastasizes to lung and liver in nude mice.
J. Cancer Res. Clin. Oncol. 108:197-203(1984) PubMed=3658923; DOI=10.1016/0143-4004(87)90053-1
Takahashi H., Adachi S., Yoshiya N., Suzuki T., Kanazawa K., Takeuchi S.
Expression of HLA-DR molecules in human gestational choriocarcinoma cell lines and malignant cell lines.
Placenta 8:293-298(1987) PubMed=3674770
Greco C., Zupi G.
Biological features and in vitro chemosensitivity of a new model of human melanoma.
Anticancer Res. 7:839-844(1987) PubMed=3046746; DOI=10.1007/BF00200019
Wong J.H., Aguero B., Gupta R.K., Morton D.L.
Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients.
Cancer Immunol. Immunother. 27:142-146(1988) PubMed=1918136; DOI=10.1083/jcb.115.1.191
Quax P.H.A., van Muijen G.N.P., Weening-Verhoeff E.J.D., Lund L.R., Dano K., Ruiter D.J., Verheijen J.H.
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
J. Cell Biol. 115:191-199(1991) PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991) PubMed=2060184; DOI=10.1007/BF01753729
van Muijen G.N.P., Cornelissen I.L.M.H.A., Jansen K.F.J., Figdor C.G., Johnson J.P., Brocker E.-B., Ruiter D.J.
Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice.
Clin. Exp. Metastasis 9:259-272(1991) PubMed=8618233; DOI=10.1093/jnci/88.7.419
Leonetti C., D'Agnano I., Lozupone F., Valentini A., Geiser T., Zon G., Calabretta B., Citro G., Zupi G.
Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
J. Natl. Cancer Inst. 88:419-429(1996) PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000) PubMed=11121133; DOI=10.1046/j.1523-1747.2000.00199.x
Lacal P.M., Failla C.M., Pagani E., Odorisio T., Schietroma C., Falcinelli S., Zambruno G., D'Atri S.
Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.
J. Invest. Dermatol. 115:1000-1007(2000) PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002) PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005) PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006) PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008) PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009) PubMed=19549886; DOI=10.1158/0008-5472.CAN-09-1528
Chambers A.F.
MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?
Cancer Res. 69:5292-5293(2009) PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S.P., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009) PubMed=19799798; DOI=10.1186/1471-2407-9-352
Casula M., Muggiano A., Cossu A., Budroni M., Caraco C., Ascierto P.A., Pagani E., Stanganelli I., Canzanella S., Sini M.C., Palomba G., Palmieri G.
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.
BMC Cancer 9:352.1-352.11(2009) DOI=10.4172/2157-7145.S2-005
Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011) PubMed=21863025; DOI=10.1038/bjc.2011.324
De Luca A., Lamura L., Strizzi L., Roma C., D'Antonio A., Margaryan N.V., Pirozzi G., Hsu M.-Y., Botti G., Mari E., Hendrix M.J.C., Salomon D.S., Normanno N.
Expression and functional role of CRIPTO-1 in cutaneous melanoma.
Br. J. Cancer 105:1030-1038(2011) PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011) PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012) PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012) PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013) PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013) PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013) PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014) PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016) PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017) PubMed=28940260; DOI=10.1002/ijc.31067
Korch C.T., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M., Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C., Healy L.E., Kniss D.A., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A., Capes-Davis A.
Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
Int. J. Cancer 142:561-572(2017) PubMed=29492214; DOI=10.18632/oncotarget.23989
Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M., Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.
Genetic alterations in main candidate genes during melanoma progression.
Oncotarget 9:8531-8541(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019) |
|---|
